{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04851613",
            "orgStudyIdInfo": {
                "id": "LAE205INT3101"
            },
            "organization": {
                "fullName": "Laekna Limited",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer",
            "officialTitle": "A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-evaluating-efficacy-safety-of-afuresertib-plus-fulvestrant-in-patients-w-locally-advanced-or-metastatic-hr-breast-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-13",
            "studyFirstSubmitQcDate": "2021-04-19",
            "studyFirstPostDateStruct": {
                "date": "2021-04-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Laekna Limited",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.",
            "detailedDescription": "Eligible patients for this study must have either (1) progressive disease whilst receiving an endocrine therapy (AI or a SERM), and/or a CDK4/6 inhibitor for locally advanced or metastatic disease; or (2) relapsed with metastatic disease whilst receiving an ET (AI or SERM), and/or a CDK4/6 inhibitor, and/or chemotherapy in adjuvant setting. No more than 2 prior lines of systemic treatments for locally advanced or metastatic disease are allowed for this study, including 1-2 prior lines of endocrine therapy, with/without CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 therapy)."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Phase I: Single-arm, open-label study to evaluate efficacy, safety, tolerability, PK of the therapy with afuresertib plus fulvestrant. Phase III: A multi-center, randomized, double-blind, placebo-controlled study to assess efficacy and safety of afuresertib/placebo plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic BC who have failed 1 to 2 prior lines of ET with/without a CDK4/6 inhibitor (up to 1 therapy), or chemotherapy (up to 1 chemotherapy).",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 256,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase I: Afuresertib and Fulvestrant Safety Run In",
                    "type": "EXPERIMENTAL",
                    "description": "Phase I: Safety run-in Cycle 1 (a cycle is 28 days) will be performed in the first 6 patients of the phase Ib. Combination regimens during the safety run-in period are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.",
                    "interventionNames": [
                        "Drug: Afuresertib"
                    ]
                },
                {
                    "label": "Phase I: Afuresertib and Fulvestrant",
                    "type": "EXPERIMENTAL",
                    "description": "Phase I: Combination regimens are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.",
                    "interventionNames": [
                        "Drug: Afuresertib"
                    ]
                },
                {
                    "label": "Phase III: afuresertib combined with fulvestrant (experimental arm)",
                    "type": "EXPERIMENTAL",
                    "description": "Phase III: afuresertib 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)",
                    "interventionNames": [
                        "Drug: Afuresertib/placebo"
                    ]
                },
                {
                    "label": "Phase III:placebo combined with fulvestrant (control arm)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "PhaseIII\uff1aplacebo combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)",
                    "interventionNames": [
                        "Drug: Afuresertib/placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Afuresertib",
                    "description": "The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles",
                    "armGroupLabels": [
                        "Phase I: Afuresertib and Fulvestrant",
                        "Phase I: Afuresertib and Fulvestrant Safety Run In"
                    ],
                    "otherNames": [
                        "Fulvestrant"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Afuresertib/placebo",
                    "description": "afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)",
                    "armGroupLabels": [
                        "Phase III: afuresertib combined with fulvestrant (experimental arm)",
                        "Phase III:placebo combined with fulvestrant (control arm)"
                    ],
                    "otherNames": [
                        "Fulvestrant"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase I: Overall Response Rate (ORR) based on RECIST 1.1",
                    "description": "Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC",
                    "timeFrame": "Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks \u00d7 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)"
                },
                {
                    "measure": "Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by investigators",
                    "description": "Phase III:To assess the anti-tumor activity of the combination therapy with afuresertib plus fulvestrant versus placebo plus fulvestrant in patients with PIK3CA/AKT1/PTEN alterations HR+/HER2- BC who have failed 1 to 2 prior lines of ET with/without a Phase III: CDK4/6 inhibitor (up to 1 therapy), or chemotherapy (up to 1 chemotherapy)",
                    "timeFrame": "Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks \u00d7 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase I: Duration of Response (DOR) based on RECIST 1.1",
                    "description": "Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC",
                    "timeFrame": "Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)"
                },
                {
                    "measure": "Phase I: Disease Control Rate (DCR) based on RECIST 1.1",
                    "description": "Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC",
                    "timeFrame": "Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)"
                },
                {
                    "measure": "Phase I: Best Overall Response (BOR) based on RECIST 1.1",
                    "description": "Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC",
                    "timeFrame": "Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)"
                },
                {
                    "measure": "Phase I: Progression Free Survival (PFS) based on RECIST 1.1",
                    "description": "Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC",
                    "timeFrame": "Phase I: After Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)"
                },
                {
                    "measure": "Phase I: Pharmacokinetics- Time to Maximum Concentration (T-Max)",
                    "description": "Phase I: Time to peak level of afuresertib",
                    "timeFrame": "Phase I: Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Phase I: Pharmacokinetics- Area Under the Curve (AUC)",
                    "description": "Area under the curve of afuresertib",
                    "timeFrame": "Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Phase I: Frequency and severity of Adverse Events (AEs)",
                    "description": "Phase I: findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0",
                    "timeFrame": "Phase I: Through study completion for an average of 12 months"
                },
                {
                    "measure": "Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by BICR",
                    "description": "Phase III: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC",
                    "timeFrame": "Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks \u00d7 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)"
                },
                {
                    "measure": "Phase III\uff1aFrequency and severity of Adverse Events (AEs)",
                    "description": "Phase III\uff1afindings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0",
                    "timeFrame": "Phase III\uff1aThrough study completion"
                },
                {
                    "measure": "Phase III\uff1aPharmacokinetics- Time to Maximum Concentration (T-Max)",
                    "description": "Time to peak level of afuresertib",
                    "timeFrame": "Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Phase III\uff1aPharmacokinetics- Area Under the Curve (AUC)",
                    "description": "Area under the curve of afuresertib",
                    "timeFrame": "Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female or male patients must be \u2265 18 years of age on the day of signing the informed consent and be able to provide written informed consent for the study.\n2. Patients with histologically or cytologically confirmed HR+/HER2- BC characterized by the absence of HER2 expression and the presence of ER and/or PR expression.\n3. HR+/HER2- BC patients must meet all the following criteria to join this study:\n\n   1. Relapsed locally advanced (LABC) or metastatic (mBC) disease; AND\n   2. Have received 1 to 2 prior lines of systemic treatments for LABC or mBC(at least one line was ET).\n4. For phase Ib part, patients must have at least one lesion that meets the definition of measurable disease by RECIST 1.1 criteria; for phase III, have measurable disease and/or at least 1 lytic or mixed (lytic + sclerotic) bone lesion that can be assessed by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible.\n5. In the Phase Ib part, Patients must provide informed consent for the procedures and the tests for PIK3CA/AKT/PTEN alterations and ESR1 mutations. The biomarkers will be tested retrospectively by gene sequencing tests using archival tumor sample (preferably within 18 months/78 weeks) or from peripheral blood or from a tumor biopsy sample. Formalin-fixed, paraffin embedded (FFPE) tissue blocksare preferred. In phase III, blood sample is mandatory for this test.\n6. In Phase III, subjects need to provide blood sample during the screening period for PIK3CA/AKT1/PTEN test, which will be conducted in the central laboratory. Only patients with PIK3CA/AKT1/PTEN alterations could include.\n7. Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.\n8. Patients who have adequate organ function\n9. Female patients of childbearing potential must have a negative pretreatment serum pregnancy test.\n10. Female patients of childbearing potential must agree to use effective contraception from enrollment to 1 year after discontinuation from the last dose of this study treatment,\n11. Patients who are able to swallow and retain oral medication and without gastrointestinal diseases to interfere with drug absorption.\n12. Patients must have no contraindications to fulvestrant.\n\nExclusion Criteria:\n\n1. Patients who had a recent major surgery that required hospitalization for longer than 48 hours (\\< 8 weeks from scheduled treatment starting date) or have used IV antibiotics for the treatment of systemic infection (\\< 2 weeks from scheduled treatment starting date).\n2. Patients who have additional known malignancies that are progressing or have required active treatments within 3 years of scheduled treatment starting date. (Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, that have undergone potentially curative therapy are not excluded).\n3. Patients who have a history of seizure or conditions that may predispose them to seizure and require anti-epileptic medications, or patients who have brain arteriovenous malformation, or intracranial masses that are causing edema or clinical symptoms.\n4. Patients who have known active CNS metastases and/or carcinomatous meningitis.\n5. Patients who had prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), or any PI3K/AKT/mTOR inhibitors, or any CDK4/6 inhibitors in phase I, II study.\n6. Patients with QT interval corrected by the Frederica's correction formula (QTcF) \\> 470 msec\n7. Patients who have uncontrolled hypertension (systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg under anti-hypertensive treatment).\n8. Patients with active Hepatitis B infection \\[defined as HBsAg (+) and HBV-DNA \u2265 200 IU/ml (1000 copy/ml)\\] or active Hepatitis C virus \\[defined as HCV antibody positive and HCV RNA (qualitative) test positive\\].\n9. Patients with known HIV seropositivity\n10. Patients who are receiving medications that are sensitive substrates of CYP3A4, OATP1B1, or BCRP with low therapeutic index.\n11. Patients who are ineligible for endocrine therapy (e.g., visceral crisis, inflammatory breast cancer).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Shimei Liu",
                    "role": "CONTACT",
                    "phone": "7037281500",
                    "email": "shimei.liu@laekna.com"
                },
                {
                    "name": "Katura Fetterson",
                    "role": "CONTACT",
                    "phone": "7037281500",
                    "email": "katura.fetterson@laekna.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Wenyue Ma",
                    "affiliation": "Laekna Limited",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Providence St. Johns Health Center",
                    "status": "RECRUITING",
                    "city": "Santa Monica",
                    "state": "California",
                    "zip": "90404",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Irving Ledesma",
                            "role": "CONTACT",
                            "phone": "310-582-7047",
                            "email": "irving.ledesmaprado@providence.org"
                        },
                        {
                            "name": "Sierra Gelsey",
                            "role": "CONTACT",
                            "email": "gelsey.sierra@providence.org"
                        },
                        {
                            "name": "Parvin Peddi, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.01945,
                        "lon": -118.49119
                    }
                },
                {
                    "facility": "Piedmont Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30318",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Trevor Feinstein, MD",
                            "role": "CONTACT",
                            "phone": "404-350-9853",
                            "email": "tfeinstein@piedmontcancerinstitute.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "University of Iowa",
                    "status": "RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sneha Padke, MD",
                            "role": "CONTACT",
                            "phone": "319-384-9502",
                            "email": "sneha-phadke@uiowa.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "University of Mississippi Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Jackson",
                    "state": "Mississippi",
                    "zip": "39216",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shou-Ching Tang, MD",
                            "role": "CONTACT",
                            "phone": "601-815-5013",
                            "email": "stang2@umc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.29876,
                        "lon": -90.18481
                    }
                },
                {
                    "facility": "University of Vermont",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Burlington",
                    "state": "Vermont",
                    "zip": "05401",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Peter Kauffman",
                            "role": "CONTACT",
                            "phone": "802-847-8400",
                            "email": "Peter.Kaufman@uvmhealth.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.47588,
                        "lon": -73.21207
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Spira, MD",
                            "role": "CONTACT",
                            "phone": "703-208-3155"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Cancer Hospital Chinese Academy of Medical Sciences",
                    "status": "RECRUITING",
                    "city": "Beijing",
                    "state": "Beijing",
                    "zip": "100021",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Hong Fang",
                            "role": "CONTACT",
                            "phone": "010-87788787",
                            "email": "cancergcp@163.com"
                        },
                        {
                            "name": "Binghe Xu, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.9075,
                        "lon": 116.39723
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077267",
                    "term": "Fulvestrant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000065171",
                    "term": "Estrogen Receptor Antagonists"
                },
                {
                    "id": "D000004965",
                    "term": "Estrogen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1723",
                    "name": "Fulvestrant",
                    "asFound": "Challenge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M8114",
                    "name": "Estrogen Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30483",
                    "name": "Estrogen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}